Fewer Steroids, No Plasma Exchange: A Change in Treatment for Vasculitis

The insights from the PEXIVAS Trial, a 10-year study, shows treatment for ANCA-associated vasculitis can become much more patient-friendly by using half the ... Read more

Bron:

Newswise: MedNews